Prevention of Future Deaths reports · 2025

Charlie Marriage

Regulation 28 report to prevent future deaths, reference 2025-0048, written 24 Jan 2025. A coroner writes one of these when an inquest reveals a risk that could cause further deaths unless something changes.

Date of report24 Jan 2025
Reference2025-0048
DeceasedCharlie Marriage
CoronerXavier Mooyaart
Coroner areaLondon Inner (South)
CategoryAlcohol, drug and medication related deaths
Sourcejudiciary.uk record · original PDF
Responses published1

The report

Text extracted from the PDF text layer. Reproduced verbatim, including the scan's own layout.

REGULATION 28:  REPORT TO PREVENT FUTURE DEATHS

1

2

3

4

REGULATION 28 REPORT TO PREVENT FUTURE DEATHS

THIS REPORT IS BEING SENT TO:

1.

, Chief Executive of NHS England, Skipton

House, 80 London Road, London, SE1 6LH

CORONER
I am Xavier Mooyaart, an assistant coroner for the coroner area of Inner
South London.

CORONER’S LEGAL POWERS
I make this report under paragraph 7, Schedule 5, of the Coroners and
Justice Act 2009 and Regulations 28 and 29 of the Coroners
(Investigations) Regulations 2013.

INVESTIGATION and INQUEST
On 1 July 2021 an investigation into the death of Charlie Marriage
commenced. The investigation concluded with an inquest hearing starting
on 9 December 2024 and a conclusion hearing on 21 January 2025. The
conclusion of the inquest was that Mr Marriage died from SUDEP (Sudden
Unexpected Death in Epilepsy), but this in the context of, and likely
contributed to, by his lack of medication, despite his efforts to obtain it
over the course of two days.

CIRCUMSTANCES OF THE DEATH
Mr Marriage had a longstanding diagnosis of idiopathic generalised
epilepsy and suffered grand mal seizures with no warning. The risk of
these had become well managed with medication, in particular Fycompa
(Perampanel). On Thursday 24 June 2021 he would finish his medication,
but he expected to pick up a repeat prescription from a pharmacy in
Uxbridge (he studied at Brunel University) the following day. He was then
notified to self-isolate for Covid, which prevented the long journey to pick
up his repeat medication. The following day he sought to obtain a new
repeat prescription via his GP practice for a local pharmacy, but this was
not recognised to be urgent in time. Both the GP practice and the
university pharmacy were closed over the weekend. On Saturday 26 June
he called 111, which promptly arranged for a “referral” for his medication
to be sent to a local pharmacy. There it was not promptly identified that
the Fycompa could not be supplied, resulting in several wasted calls to
111, and the loss of time and motivation. He was referred back to 111 by
the pharmacist, though it was they that should have sought to find a
solution. 111 identified that a clinician would be required to help resolve
the situation, but Mr Marriage did not receive a call back from one. That

1

 5

night he suffered a seizure that caused his death at home. The lack of
Fycompa likely increased the prospect of a severe seizure and
contributed to his death. The growing risk of him suffering SUDEP over the
48 hours since his last dose had not been recognised or resulted in
appropriate prioritisation, safety-netting, or an emergency supply.

CORONER’S CONCERNS
During the course of the inquest the evidence revealed matters giving rise
to concern. In my opinion there is a risk that future deaths could occur
unless action is taken. In the circumstances it is my statutory duty to
report to you.
The MATTERS OF CONCERN are as follows.  –
(1) There are cohorts of patients who are medication dependant. For
some their underlying condition is such that absent this medication they
are at significant risk of a sudden crisis, and potentially death e.g. SUDEP,
or Diabetic Ketoacidosis etc. These were described at the inquest as
“cliff-edge conditions”.
(2) It is not apparent that these patients are currently identified within the
health system as being at risk of a sudden crisis and death (absent their
medication) so as to manage the following concerns giving rise to a risk of
future deaths:
(a) that such patients may not be fully aware of the risks of death
associated with not being medicated and therefore may (i) not fully
understand the importance of avoiding the risk that this scenario arises,
and (ii) not have planned the likely best course of action in the event that it
does (e.g. to go to A&E, or to approach an identified pharmacy for an
emergency supply);
(b) that the potential urgency and level of danger is not quickly identified
and understood in the scenario where they seek medical advice and/or
medication (i.e. that their potential vulnerability is not well recognised
and communicated on/within the medical records accessed by those in
the health sector, such that patients are not supported with appropriate
urgency or safety-netting advice);
(c) that it is not recognised that sending to them to a pharmacy may not
reliably mitigate their risks quickly where it is unlikely the medication can
be expected to be in stock (i.e. the risk that it may not be identified that for
some patients their medication is not likely easily available on an ad hoc
local basis); and
(d) that they are given generic safety-netting/worsening advice, whereas
such patients may not present with any developing or new before
suffering a sudden crisis and therefore remain at significant risk without
medical oversight until appropriately medicated.

6

ACTION SHOULD BE TAKEN
In my opinion action should be taken to prevent future deaths and I
believe NHS-England has the power to take such action.

2

 YOUR RESPONSE
You are under a duty to respond to this report within 56 days of the date of
this report, namely by Tuesday 25th March 2025. I, the coroner, may
extend the period.
Your response must contain details of action taken or proposed to be
taken, setting out the timetable for action. Otherwise, you must explain
why no action is proposed.

COPIES and PUBLICATION
I have sent a copy of my report to the Chief Coroner and to the following
other Interested Persons: the family of Mr Marriage, the Waterloo Health
Centre, a then receptionist for the GP practice, SuperDrug, the locum
pharmacist employed in a particular SuperDrug branch at the time, the
London Ambulance Service, and Derbyshire Health United.
I am also under a duty to send a copy of your response to the Chief
Coroner and all interested persons who in my opinion should receive it.
I may also send a copy of your response to any other person who I believe
may find it useful or of interest.
The Chief Coroner may publish either or both in a complete or redacted or
summary form. He may send a copy of this report to any person who he
believes may find it useful or of interest.
You may make representations to me, the coroner, at the time of your
response, about the release or the publication of your response by the
Chief Coroner.

7

8

9

24 January 2025

3

Responses

1 response published against this report on judiciary.uk. A response is a body's written reply to the coroner's concerns; publication is at the discretion of the Chief Coroner's office, so an absent response does not mean nobody replied.

Response from NHS England (PDF)
Mr Xavier Mooyaart 
HM Assistant Coroner 
Inner South London 
Southwark Coroner’s Court  
1 Tennis Street 
London  
SE1 1YF 

Dear Coroner, 

National Medical Director  
NHS England  
Wellington House 
133-155 Waterloo Road  
London 
SE1 8UG 

24 March 2025  

Re: Regulation 28 Report to Prevent Future Deaths – Charlie Marriage who died 
on Saturday 26 June 2021 

Thank  you  for  your  Report  to  Prevent  Future  Deaths  (hereafter  “Report”)  dated  24 
January 2025 concerning the death of Charlie Marriage on Saturday 26 June 2021. In 
advance of responding to the specific concerns raised in your Report, I would like to 
express my deep condolences to Charlie’s family and loved ones. NHS England are 
keen to assure the family and the  Coroner that the concerns raised about  Charlie’s 
care and the circumstances surrounding his death have been listened to and reflected 
upon.   

Your Report raises concerns over the risks to patients who are medication dependent, 
who may be at significant risk of sudden crisis or death without their medication. You 
have raised that these patients may not be fully aware of the risks of death associated 
with not being medicated, and that the potential urgency and level of danger created 
by an absence of medication is not quickly identified and understood when patients 
seek medical advice and/or medication.  

Your Report raises important insights around “cliff-edge conditions” such as epilepsy, 
particularly  where  a  patient’s  condition  may  deteriorate  very  rapidly  without  any 
obvious worsening signs or where their potential vulnerability is not recognised. You 
have also noted that sending patients to a pharmacy may not reliably mitigate their 
risks quickly, especially where their medication is not  easily available on an ad hoc 
local basis and may not be in stock.  

NHS  England  has  instigated  the  Medicines  Safety  Improvement  Programme  which 
has  been  working  to  improve  access  to  “Time  Critical  Medicines”.  The  focus  of 
attention is to identify people with “cliff-edge conditions” and then to ensure they have 
the time critical medicines they need to prevent rapid deterioration. The programme 
started in 2024 and has identified a small number of “cliff-edge conditions” that may 
benefit from improved processes. Epilepsy is one of the conditions identified, and a 
key  ambition  of  the  programme  is  to  improve  care  for  people  with  epilepsy.  This 
programme is being delivered in partnership with Epilepsy Action and Parkinson’s UK 
(alongside  other  charities)  and  is  planned  to  run  until  March  2027.  It  will  take  into 
account the learning from Charlie’s death.  

                                                                                                                       
 
 
 
 
 
 
  
 
 
 
 
 
  
 All NHS Services are required to adhere to the National Institute for Health and Care 
Excellence (NICE) guidelines. This is a professional and contractual imperative. The 
NICE Guidelines on Epilepsy (NG217, published in April 2022 and updated in January 
2025)  require  specialist  clinicians  to:  “Discuss  with  people  with  epilepsy,  and  their 
families  and  carers  if  appropriate,  their  individual  risk  of  epilepsy-related  death, 
including  SUDEP,  from  the  time  of  diagnosis  onwards.”  (see  10.1.4).  It  is  also  a 
requirement to: “Arrange regular (at least annual) monitoring reviews for adults with 
epilepsy”,  including  those  with  “a  high  risk  of  sudden  unexpected  death  in  epilepsy 
(SUDEP)” (see 4.4.1).  

The September 2021 national specialty report for neurology from the Getting It Right 
First Time (GIRFT) programme focuses on improving access to care for patients with 
neurological  disorders  across  England,  including  patients  with  intermittent  and 
unpredictable conditions such as epilepsy  (Neurology  -  Getting It Right  First Time  - 
GIRFT).  This  programme  follows  on  from  Charlie’s  death  and  will  increase  the 
opportunity for patients to have these important discussions. 

The National Institute for Health and Care Excellence has also published guidance for 
pharmacists  on  making  an  emergency  supply  of  medication,  which  reinforces  the 
guidance of the Royal Pharmaceutical Society which states: “The pharmacist should 
consider the medical consequences of not supplying a medicine in an emergency” and 
“If  the  pharmacist  is  unable  to  make  an  emergency  supply  of  a  medicine  the 
pharmacist should advise the patient how to obtain essential medical care.”  

NHS  England,  alongside  the  Department  of  Health  and  Social  Care  (DHSC), 
previously  issued  guidance  in  November  2019  on  how  clinicians  should  manage 
instances  where  medication  is  needed  urgently  and  when  it  is  in  short  supply.  This 
states:  “In  all  cases  of  medicines  supply  issues,  community  pharmacies  should 
endeavour to communicate any supply issues and relevant information about resupply 
dates  and  the  proposed  management  plan  clearly  with  patients.  They  should  also 
undertake counselling to support affected patients where possible.” (see 11.1.3).  

This guidance is further supported by the service specification for the NHS Pharmacy 
First service that was launched on 31 January 2024 (NHS England » Launch of NHS 
Pharmacy First advanced service). In cases where medication that is urgently required 
is not in stock at the pharmacy, the service specification states that, with the agreement 
of  the  patient,  the  pharmacist  should  identify  another  pharmacy  that  provides  the 
service and forward the electronic referral to them (see 4.19). If the patient is unable 
to get to the premises, the pharmacist must ensure that the patient is able to obtain 
the supply in a timely manner by discussing all reasonable options for accessing their 
medicines (see 4.20). 

Current  technology  does  not  allow  the  tracking  of  stocks  of  medication  across 
community pharmacies. This is being investigated as a strategy to better manage high-
impact national shortages of medication. 

 
 
 
 
 
 
 The  Royal  Pharmaceutical  Society    (RPS)  and  the  Royal  College  of  General 
Practitioners (RCGP) have published a toolkit for GP practices to use, to assess and 
improve the safety and effectiveness of their repeat prescribing systems. This toolkit 
highlights the need for practices to ensure that they have taken into account high risk 
medicines. The medicines it identifies as high risk are those that are most commonly 
associated  with  serious  adverse  reactions,  but  it  is  not  specific  to  medication  for 
epilepsy.  The  toolkit    recommends  using  the  following  text  as  an  example  of 
information that practices might share with patients about repeat prescriptions:  
“Please try not to run out of your medicines. When you are running low, e.g., have two 
weeks’ supply remaining, please request the next prescription. If you accidentally run 
low or run out, we will try to process your request as quickly as possible, but please 
remember that the request process must be carried out thoroughly and safely and that 
GP practice teams are extremely busy. Emergency supply requests for medicine can 
be requested from NHS 111 or 111 Online in an urgent situation. The pharmacy will 
check  the  GP  record/National  Care  Record  to  ensure  that  they  are  not  making 
duplicate supplies to ensure your safety and reduce waste.”  

When a patient identifies to NHS 111 that they have run out of medication, the caller 
will establish when the next dose is due. If a prescription cannot be sourced from the 
patient's  own  GP  within  this  time  period,  the  patient  is  referred  to  an  open  local 
pharmacy  under  the  Pharmacy  First  Scheme,  once  it  has  been  confirmed  that  the 
patient does not need a symptomatic assessment. 

All  medications  are  treated  with  the  same  high  priority.  Due  to  the  variable  use  of 
medications  for  different  presentations,  the  use  of  brand  names  and  alternative 
descriptions  for  conditions,  it  is not  safely possible  to  differentiate between  different 
levels of urgency. 

We note that at the time of this incident, England still had legal restrictions in place to 
prevent Covid-19 deaths. Primary care and community pharmacies were under huge 
amounts  of  pressure,  whist  maintaining  necessary  but  burdensome  infection 
prevention  measures.  Since  this  time,  we  have  taken  steps  to  increase  access  to 
primary  care  services,  including  a  shift  to  digital  services  and  a  reduction  in  the 
bureaucratic load on general practice, and the commissioning of the Pharmacy First 
to better support people who need urgent access to medicines. 

I  would  also  like  to  provide  further  assurances  on  the  national  NHS  England  work 
taking  place  around  the  Reports  to  Prevent  Future  Deaths.  All  reports  received  are 
discussed  by  the  Regulation  28  Working  Group,  comprising  Regional  Medical 
Directors,  and  other  clinical  and  quality  colleagues  from  across  the  regions.  This 
ensures  that  key  learnings  and  insights  around  events,  such  as  the  sad  death  of 
Charlie, are shared across the NHS at both a national and regional level and helps us 
to  pay  close  attention  to  any  emerging  trends  that  may  require  further  review  and 
action.   

 
 
 
 
 
 Thank you for bringing these important patient safety issues to my attention and please 
do not hesitate to contact me should you need any further information.  

Yours sincerely,  

National Medical Director

Related reports

Other reports by Xavier Mooyaart

See all →

More reports categorised “Alcohol, drug and medication related deaths”

See all →

Track Alcohol, drug and medication related deaths

See every Prevention of Future Deaths report matching Alcohol, drug and medication related deaths, and how often a new one appears.

What would an alert for this have sent me? Search the full text

Free to try — the preview shows the real matches and how many arrived in the last 12 months. Your first email alert is free.

These reports are published by the Chief Coroner's office at judiciary.uk and are © Crown copyright. The text here is reproduced from the published PDF so it can be searched. If something on this page is wrong, or you are a person named in it and want it reviewed, email drcjar@gmail.com and we will act promptly.